Published in final edited form as:

Angew Chem Int Ed Engl. 2014 September 8; 53(37): 9851–9855. doi:10.1002/anie.201406622.

Simple Sulfinate Synthesis Enables C–H Trifluoromethylcyclopropanation

Ryan Gianatassio,

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Shuhei Kawamura,

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Cecil L Eprile,

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Klement Foo,

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Jason Ge,

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Aaron C. Burns,

Department of Chemistry, Pfizer Pharmaceuticals, La Jolla Laboratories, 10770 Science Center Drive, La Jolla, California 92121

Michael R. Collins, and

Department of Chemistry, Pfizer Pharmaceuticals, La Jolla Laboratories, 10770 Science Center Drive, La Jolla, California 92121

Phil S. Baran

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Phil S. Baran: pbaran@scripps.edu

Abstract

A simple method to convert readily available carboxylic acids into sulfinate salts employing an interrupted Barton decarboxylation reaction is reported. A medically oriented panel of ten new sulfinate reagents was created using this method, including a key trifluoromethylcyclopropanation reagent TFCS-Na. The reactivity of six of these salts towards C–H functionalization was field-tested using several different classes of heterocycles.

Correspondence to: Phil S. Baran, pbaran@scripps.edu.

Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

Keywords

bioisosteres; sulfinate salts; heterocycles; C–H functionalization; analogue synthesis

The decoration of C–H bonds on heteroarenes using radicals generated from sulfinate salts has emerged as a predictable and chemoselective method for both the early and late stages of a synthesis,¹ for the prediction and prevention of drug metabolism,² and for the native chemical tagging of complex molecules.³ In a recent report, a sulfinate salt was used to append a trifluoromethyl group onto (–)-agelastatin A, which led to the synthesis of the most potent derivative of this natural product.⁴ The surging commercial demand for sulfinate reagents pointed to a clear drawback in that only a limited set are currently available. In contrast to their more widely available relatives, carboxylic acids, sulfonates have a significantly weaker barrier for homolysis leading to alkyl radicals (as judged by bond dissociation energies, Figure 1A). The relatively weak C–S bond in sulfonates makes them ideal radical precursors as compared to carboxylic acids which often require strong oxidants, heat, light, specialized transition metal catalysts, or further functionalization.⁵ In this communication, we report a simple procedure for the conversion of a variety of carboxylic acids to sulfinate salts thus enabling the direct synthesis of a variety of important bioisosteres and setting the stage for significant expansion of the commercially available sulfinate toolkit.

The invention of a route to sulfinate salts from carboxylic acids was actually prompted by a recent report from a group at Novartis where the trifluoromethylcyclopropyl group was found to function as a metabolically stable replacement for a *tert*-butyl moiety.⁶ The introduction of this group was problematic, and the reported method requires a multi-step synthesis (using diazomethane), thus making it an excellent candidate for a C–H functionalization strategy using sulfonates. The commercial availability of acid **1** conveniently allowed us to determine if it was even necessary to invent such a reagent bearing this motif (**2**). As shown in Figure 1B, classic Minisci conditions were screened using a variety of acids and temperatures with caffeine as the test substrate, and no product (**2A**) was detected by LC/MS. These findings are consistent with our previous studies where Minisci conditions generally fail when using fluorinated acids.¹ We then turned to Barton's classic work on visible light mediated photolytic radical formation from *O*-esters of thiohydroxamic acids.⁷ Acid **1** was converted to ester **3**, which was subjected to Barton's conditions for the generation of alkyl radicals and Minisci-type addition in the presence of a Brønsted acid.⁸ Although we were able to reproduce the reported addition of adamantyl radical to caffeine, the identical conditions using **3** as radical donor in either DMF or CH₂Cl₂ led to less than 1% conversion by LC/MS. Upon further analysis, the attempted homolysis of **3** led to small quantities of thiopyridyl substrate **4**, an intermediate that represented a possible pathway to sulfinate **2**. After extensive solvent screening, ethyl acetate was found to be the optimal medium to obtain synthetically useful yields of **4**. This empirical finding is useful given the reported inefficiency of the "interrupted" Barton decarboxylation on small-sized ring systems. Subsequent oxidation using RuCl₃ was facile and cleavage of pyridine with NaOEt led to the coveted trifluoromethylcyclopropyl sulfinate salt in 75% isolated yield (TFCS-Na, **2**, structure verified by x-ray, CCDC # 1010780). To

our delight, when caffeine was exposed to sulfinate salt **2** (3.0 equiv) and TBHP (5.0 equiv) at 60 °C significant amounts of **2A** were observed by LC/MS. After screening various solvents and temperatures, a mixture of diethylcarbonate and water (3: 2) at 90 °C led to a 71% isolated yield of **2A** after only one hour. The elevated temperature relative to other sulfinate additions is presumably required to generate the radical and forge the quaternary carbon center.

As illustrated in Table 1, this protocol for the net conversion of carboxylic acids to sulfinate salts is simple and general. The sequence involves only one isolated intermediate (sulfone) with the intermediate Barton ester carried on crude after aqueous workup, and the rearranged sulfide submitted directly to the RuCl₃-catalyzed oxidation. Ten different sulfinate reagents were prepared using this route and ranged in structural complexity, fluorine content, and heteroatom presence.⁹

In addition to TFCS-Na **2**, several other salts may find use in medicinal chemistry programs. It is important to note that difluorinated congeners of common cyclic ethers were synthesized as isosteric replacements of oxygen (e.g. **14**). Azetidine **23** could be used to increase solubility of medicinally relevant compounds, and removal of the Boc group could lead to further derivatization. Other sulfonates such as **17**, **20**, and **29** contain motifs popular in medicinal chemistry¹⁰ and they were selected for commercialization. As such, their synthesis was conducted on multi-gram scale.

The C–H functionalization of four different classes of heterocycles **A–D** was explored with these six newly commercialized sulfinate salts (Table 2). All of these sulfonates gave products in good to moderate yields. As can be expected with sulfinate chemistry, these reactions are conducted under air, in the presence of water, and without using transition metals, which makes them very practical and operationally simple. As observed with **1** (Figure 1B), standard Minisci reaction conditions were screened with caffeine (RCO₂H, AgNO₃, (NH₄)₂S₂O₈ and H₂SO₄ in H₂O at 90 °C) using **12**, **15**, **18**, **21**, and **27**, but zero or slight conversion (less than 5%) was observed.¹¹ Although we only tested the potential of some of these new salts for C–H functionalization, sulfinate salts have shown reactivity in cross-coupling and can be converted to other functional groups such as sulfonamides.^{12,13}

This method compares well with other state-of-the-art routes to introduce medicinally important functional groups onto heteroarenes. For example, sulfinate salt **14** allows for the facile attachment of a difluorinated isostere of a tetrahydropyran ring onto a heterocycle, which would otherwise require 4 steps to install starting from the corresponding carboxylic acid.¹⁴ Another method to directly append tetrahydropyran, tetrahydrofuran, azetidine, and cyclobutane rings onto heteroarenes has been developed by Molander.¹⁵ Also, a trifluoropropyl group can be incorporated into a heteroarene through a condensation reaction with 4,4,4-trifluorobutanal, 2-oxopropanal and ammonium hydroxide.¹⁶ However, the only method to directly append a cyclopropyltrifluoromethyl group onto a heteroarene is achieved using sulfinate radical chemistry.

Lastly, attention was turned to one of the highlighted substrates in the Novartis report: bis-pyridine **35** (Scheme 1). The reported synthesis started from **33**, a compound with limited

availability but easily prepared from 2,5-dibromopyridine. Three steps are required to convert **33** to the trifluoromethylcyclopropyl pyridine **34**. A final (presumably unoptimized) Suzuki coupling proceeded in 3% yield to furnish **35**. In stark contrast, commercially available pyridine **36** bearing a C-3 boron functionality could be trifluoromethylcyclopropanated using **2** to chemoselectively furnish **37**. This intermediate was used directly without isolation or purification in a Suzuki coupling to afford **35** in 37% isolated yield over the two-step, one-pot operation.

In summary, a simple sequence to convert widely available carboxylic acids into sulfinate salts has been devised using classic Barton chemistry. Several of these salts were commercialized and used to functionalize a panel of heterocycles. The simplicity of this C–H functionalization (a cheap industrial oxidant, simple solvent, and no metals) is a clear advantage over other radical donors. Judging from the demonstrated utility of these and other sulfinate salts at Pfizer we anticipate their rapid adoption for use in drug discovery.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support for this work was provided by the NIH/NIGMS (GM-106210), Sigma-Aldrich, Inc., Pfizer, Inc., Uehara Memorial Foundation (postdoctoral fellowship for S. K.), and A*STAR (predoctoral fellowship for K. F.). We are grateful to Prof. A. L. Rheingold and Dr. C. E. Moore (UCSD) for X-ray crystallographic analysis, Dr. D.-H. Huang and Dr. L. Pasternack for assistance with NMR spectroscopy, and M. A. Ornelas for technical assistance.

References

1. a) Ji Y, Brueckl T, Baxter RD, Fujiwara Y, Seiple IB, Su S, Blackmond DG, Baran PS. *Proc. Natl. Acad. Sci. USA*. 2011; 108:14411–14415. [PubMed: 21844378] b) Fujiwara Y, Dixon JA, Rodriguez RA, Baxter RD, Dixon DD, Collins MR, Blackmond DG, Baran PS. *J. Am. Chem. Soc.* 2012; 134:1494–1497. [PubMed: 22229949] c) Fujiwara Y, Dixon JA, O'Hara F, Daa Funder E, Dixon DD, Rodriguez RA, Baxter RD, Herlé B, Sach N, Collins MR, Ishihara Y, Baran PS. *Nature*. 2012; 492:95–99. [PubMed: 23201691] d) Zhou Q, Ruffoni A, Gianatassio R, Fujiwara Y, Sella E, Shabat D, Baran PS. *Angew. Chem. Int. Ed.* 2013; 52:3949–3952.
2. O'Hara F, Burns AC, Collins MR, Dalvie D, Ornelas MA, Vaz ADN, Fujiwara Y, Baran PS. *J. Med. Chem.* 2014; 57:1616–1620. [PubMed: 24472070]
3. Zhou Q, Gui J, Pan C-M, Albone E, Cheng X, Suh EM, Grasso L, Ishihara Y, Baran PS. *J. Am. Chem. Soc.* 2013; 135:12994–12997. [PubMed: 23957305]
4. Stout EP, Choi M, Castro JE, Molinski TF. *J. Med. Chem.* 2014 *ASAP*.
5. a) Haynes, WM., editor. *Bond Dissociation Energies in CRC Handbook of Chemistry and Physics*, 95th Edition (Internet Version 2015). Boca Raton, FL: CRC Press/Taylor and Francis; b) Good A, Thynne JCJ. *Trans. Faraday Soc.* 1967; 63:2708–2720.
6. Barnes-Seeman D, Jain M, Bell L, Ferreira S, Cohen S, Chen XH, Amin J, Snodgrass B, Hatsis P. *ACS Med. Chem. Lett.* 2013; 4:514–516. [PubMed: 24900702]
7. a) Barton DHR, Crich D, Motherwell WB. *J. Chem. Soc., Chem. Commun.* 1983:939–941. b) Barton DHR, Kretzschmar G. *Tetrahedron Lett.* 1983; 24:5889–5892. c) Barton DHR, Crich D, Kretzschmar G. *Tetrahedron Lett.* 1984; 25:1055–1058. d) Barton DHR, Crich D, Potier P. *Tetrahedron Lett.* 1985; 26:5943–5946. e) Barton DHR, Crich D, Motherwell WB. *Tetrahedron*. 1985; 41:3901–3924. f) Barton DHR, Bridon D, Zard SZ. *Heterocycles*. 1987; 25:449–462. g) Barton DHR, Bridon D, Fernandez-Picot I, Zard SZ. *Tetrahedron*. 1987; 43:2733–2740. h) Barton DHR, Lacher B, Misterkiewicz B, Zard SZ. *Tetrahedron*. 1988; 44:1153–1158. i) Barton DHR, Ozbalik N,

- Vacher B. *Tetrahedron*. 1988; 44:3501–3512.j) Barton DHR, Halley F, Ozbalik N, Schmitt M, Young E, Balavoine G. *J. Am. Chem. Soc.* 1989; 111:7144–7149.k) Barton DHR, Jaszberenyi JC, Tang D. *Tetrahedron Lett.* 1993; 34:3381–3384.l) Barton DHR, Chern C-Y, Jaszberenyi JC, Shinada T. *Tetrahedron Lett.* 1993; 34:6505–6508.m) Barton DHR, Gateau-Olesker A, Géro SD, Lacher B, Tachdjian C, Zard SZ. *Tetrahedron*. 1993; 49:4589–4602.n) Barton DHR, Liu W. *Tetrahedron Lett.* 1997; 38:2431–2434.
8. a) Castagnino E, Corsano S. *Tetrahedron Lett.* 1986; 27:6337–6338.b) Barton DHR, Garcia B, Togo H, Zard SZ. *Tetrahedron Lett.* 1986; 27:1327–1330.
9. It has been shown that potassium trifluoromethanesulfinate can be prepared from potassium trifluoroacetate by treatment with SO₂ (g) at 140 °C in DMF. See: Besson B. US2009/216036. 2009
10. a) Desai RC, Gratale DF, Han W, Koyama H, Metzger E, Lombardo VK, MacNaul KL, Doebber TW, Berger JP, Leung K, Franklin R, Moller DE, Heck JV, Sahoo SP. *Bioorg. Med. Chem. Lett.* 2003; 13:3541–3544. [PubMed: 14505666] b) Ontoria JM, Bufi LL, Torrisi C, Bresciani A, Giomini C, Rowley M, Serafini S, Bin H, Hao W, Steinkuhler C, Jones P. *Bioorg. Med. Chem. Lett.* 2011; 21:5274–5282. [PubMed: 21803580] c) Liu L, Norman MH, Lee M, Xi N, Siegmund A, Boezio AA, Booker S, Choquette D, D'Angelo ND, Germain J, Yang K, Yang Y, Zhang Y, Bellon SF, Whittington DA, Harmange JC, Dominguez C, Kim TS, Dussault I. *J. Med. Chem.* 2012; 55:1868–1897. [PubMed: 22320327] d) Waddell ST, Santorelli GM, Maletic MM, Leeman AH, Gu X, Graham DW, Balkovec JM, Aster SD. US2004/133011. 2004
11. Jain R, Vaitilingam B, Nayyar A, Palde PB. *Bioorg. Med. Chem. Lett.* 2003; 13:1051–1054. [PubMed: 12643909]
12. a) Li ZJ, Cui ZL, Liu ZQ. *Org. Lett.* 2013; 15:406–409. [PubMed: 23305217] b) Ye YD, Kuenzi SA, Sanford MS. *Org. Lett.* 2012; 14:4979–4981. [PubMed: 22984900]
13. a) Alig L, Alsenz J, Andjelkovic M, Bendels S, Bernardeau A, Bleicher K, Bourson A, David-Pierson P, Guba W, Hildbrand S, Kube D, Lubbers T, Mayweg AV, Narquizian R, Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, Rover S, Schneider G, Taylor S, Waldineier P. *J. Med. Chem.* 2008; 51:2115–2127. [PubMed: 18335976] b) Johnson MW, Bagley SW, Mankad NP, Bergman RG, Mascitti V, Toste FD. *Angew. Chem. Int. Ed.* 2014; 53:4404–4407.
14. Banville J, Rémillard R, Ruediger EH, Deon DH, Gagnon M, Dube L, Guy J, Priestly ES, Posy SL, Maxwell BD, Wong PC. WO2013/163279. 2013
15. a) Presset M, Fleury-Bregeot N, Oehrich D, Rombouts F, Molander GA. *J. Org. Chem.* 2013; 78:4615–4619. [PubMed: 23594305] b) Molander GA, Colombel V, Braz VA. *Org. Lett.* 2011; 13:1852–1855. [PubMed: 21391555]
16. Malmas MS, Ni Y, Edrei JJ, Stange H, Schindler R, Hofgen N, Egerland U, Langen B. US2009/14336. 2009
17. Oballa R. WO2006/133559. 2006

Figure 1.

A. Logic behind conversion of carboxylic acids to sulfinates; ubiquitous but less reactive carboxylic acids could be used as precursors to rare but useful sulfinates. **B.** The “interrupted” Barton reaction allows for the development of a high-value reagent for the introduction of isosteric units for medicinal chemistry.

Scheme 1.

Comparison of conventional and C-H functionalization routes to **35**. A) Reaction performed on 0.05 mmol scale. Reagents and conditions: **36** (1 equiv), **2** (3.0 equiv), *tert*-butylhydroperoxide (TBHP, 5.0 equiv), 0 to 90 °C; then 2-bromo-5-cyanopyridine (1.1 equiv), $\text{Pd}(\text{PPh}_3)_4$, DME:H₂O (3:1), reflux.

Table 1

Conversion of readily available carboxylic acids into sulfinate reagents. Conditions: A) carboxylic acid (1 equiv), (COCl)₂ (1.5 equiv), DMF (0.1 equiv), 0 to 23 °C; B) 250 W or 600 W tungsten lamp, EtOAc; C) RuCl₃ (5 mol%), NaIO₄ (6 equiv), EtOAc:H₂O; D) NaOEt (1.1 equiv), DMA, 0 to 30 °C or NaSEt, THF, 0 to 23 °C.

carboxylic acid	sulfone	sulfinate salt	carboxylic acid	sulfone	sulfinate salt
 1	 5 (50%)	 2 (75%)[x-ray]	 18	 19 (71%)	 20 (34%)
 6	 7 (30%)	 8 (35%)	 21	 22 (42%)	 23 (63%)
 9	 10 (47%)	 11 (30%)	 24	 25 (71%)	 26 (50%)
 12	 13 (78%)	 14 (73%)	 27	 28 (92%)	 29 (88%)
 15	 16 (56%)	 17 (98%)	 30	 31 (42%)	 32 (95%)

Table 2

Reactions of newly designed sodium alkanesulfinate salts and heteroarenes. Reactions were performed on 0.1 or 0.2 mmol scale. Standard conditions: Heterocycle (1 equiv), sulfinate salt (3 equiv), *tert*-butyl hydroperoxide (TBHP, 5.0 equiv), 0 to 90 °C. Yields of chromatographically pure products are displayed, unless otherwise noted.

	 A	 B	 C	 D
 TFCS-Na (2) [790184] ^a	 2A (71%)	 2B (77%)	 2C (56%)	 2D (37%)
 DFHS-Na (14) [ALD00230] ^a	 14A (67%)	 14B (90%)	 14C (55%)	 14D (36%)
 THPS-Na (17) [ALD00232] ^a	 17A (67%) ^b	 17B (90%) ^b	 17C (49%) ^b	 17D (37%) ^b
 THFS-Na (20) [ALD00234] ^a	 20A (49%) ^b	 20B (44%) ^b	 20C (29%) ^b	 20D (31%) ^b
 AZS-Na (23) [ALD00236] ^a	 23A (46%)	 23B (84%)	 23C (33%)	 23D (27%)
 TFPS-Na (29) [ALD00238] ^a	 29A (49%)	 29B (53%)	 29C (45%)	 29D (23%)

^a Sigma–Aldrich Catalog number.

^b 6.0 equiv of the sulfinate salt and 10 equiv of TBHP were used.